LTRN (Lantern Pharma Inc) Net earnings per share (EPS TTM)

Partnerships with research institutes and cloud services for patient recruitment in trials are driving the price action for Lantern Pharma Inc. (LTRN). The trailing 12-month earnings per share helps assess the impact of declining demand on per-unit earnings, where -1.61 represents the current metric. Capex and balance sheet efficiency are based on the RADR AI platform, while the actual financial impact is currently delivered by targeted molecules through agreements.
Lantern - analytical breakdowns and key metrics (LTRN)

A defensive portfolio is constructed through the rigorous selection of assets with sustainable yields. This indicator calculates annual net income divided by the total number of shares, excluding the impact of one-off transactions. For Lantern Pharma Inc. (LTRN), the precision of AI diagnostics in oncology enables the company to increase therapy costs, directly impacting this result. Profit growth confirms the effectiveness of the business model. By analyzing the rolling annual earnings per share, an investor can identify the risks of buying at local peaks.